<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198116</url>
  </required_header>
  <id_info>
    <org_study_id>2000026630</org_study_id>
    <secondary_id>R01DA047986</secondary_id>
    <nct_id>NCT04198116</nct_id>
  </id_info>
  <brief_title>Combining Varenicline and Guanfacine for Smoking Cessation</brief_title>
  <official_title>Combining Varenicline and Guanfacine for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The novel design of this study combines a laboratory paradigm to evaluate stress-induced&#xD;
      smoking behavior and smoking-related reinforcement, followed by a 12-week treatment phase to&#xD;
      evaluate clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a double-blind, this Phase 2 study will randomize 140 smokers to a parallel group&#xD;
      design (varenicline + guanfacine vs. varenicline alone). Following titration to steady state&#xD;
      levels, the investigators will evaluate sex differences in medication effects on&#xD;
      stress-induced smoking behavior and smoking-related reinforcement in the laboratory, and on&#xD;
      abstinence outcomes during a subsequent 12-week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency</measure>
    <time_frame>50 minutes</time_frame>
    <description>Latency (in minutes) to time of first cigarette smoked during the delay period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Varenicline + Guanfacine ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline 2mg/day</description>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_label>Varenicline + Guanfacine ER</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine ER</intervention_name>
    <description>Guanfacine Extended Release (6mg/day ER)</description>
    <arm_group_label>Varenicline + Guanfacine ER</arm_group_label>
    <other_name>Intuniv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18+&#xD;
&#xD;
          2. Able to read and write English&#xD;
&#xD;
          3. SMOKER: 10 or more cigarettes per day for at least the past year, Carbon Monoxide (CO)&#xD;
             &gt; 10 ppm at intake&#xD;
&#xD;
          4. Able to take oral medications and willing to adhere to medication regimen&#xD;
&#xD;
          5. Provide evidence of a stable living residence in the last 2 months prior to&#xD;
             randomization, have reasonable transportation arrangements to the study site, have no&#xD;
             plans to move within the next 3 months, and have no unresolved legal problems&#xD;
&#xD;
          6. Motivated to quit smoking (8 or greater on the Contemplation Ladder)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any significant current medical conditions (neurological, cardiovascular&#xD;
             [including hypertension or hypotension: sitting BP &gt;160/100 or &lt;90/60mmHg at baseline&#xD;
             screening], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations,&#xD;
             or other unstable medical conditions&#xD;
&#xD;
          2. Current Diagnostic and Statistical Manual of Mental Disorders (DSM-V) alcohol or&#xD;
             substances use disorders, other than mild alcohol use disorder or tobacco use disorder&#xD;
&#xD;
          3. Subjects who have a positive test result at intake appointment on urine drug screens&#xD;
             conducted for illicit drugs&#xD;
&#xD;
          4. Past 30 day use of psychoactive drugs excluding anxiolytics and antidepressants&#xD;
             (however, see #10; barbiturates, benzodiazepines are exclusionary)&#xD;
&#xD;
          5. Women who are pregnant or nursing, or fail to use one of the following methods of&#xD;
             birth control unless she or partner is surgically sterile or she is postmenopausal&#xD;
             (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive&#xD;
             sponge, double barrier [diaphragm or condom plus spermicide], or IUD)&#xD;
&#xD;
          6. Suicidal, homicidal or evidence of current (past 6-month) severe mental illness such&#xD;
             as schizophrenia or bipolar disorder&#xD;
&#xD;
          7. meeting DSM-V criteria for current (past-6 month) attention deficit hyperactivity&#xD;
             disorder (ADHD)&#xD;
&#xD;
          8. Individuals who are currently taking medications known to be effective for smoking&#xD;
             cessation (e.g., FDA smoking cessation medications, nortriptyline, clonidine) or are&#xD;
             regular users of e-cigarettes or other tobacco projects (pipe, cigar, smokeless&#xD;
             tobacco) in the past 30 days&#xD;
&#xD;
          9. Only one member per household can participate in the study&#xD;
&#xD;
         10. Specific exclusions for administration of guanfacine not already specified: EKG&#xD;
             evidence at baseline screening of any clinically significant conduction abnormalities&#xD;
             or arrhythmias; known intolerance for guanfacine or any alpha blocker; history of&#xD;
             fainting, syncopal attacks, heart failure or myocardial infarction, or impaired liver&#xD;
             (aspartate aminotransferase [AST], alanine aminotransferase [ALT] &gt; 3x normal) or&#xD;
             renal function (estimated creatinine clearance &lt;60 cc/min); treatment with any&#xD;
             antihypertensive drug or any alpha-blocker; use of any central nervous system (CNS)&#xD;
             depressant (e.g., phenothiazines, barbiturates, benzodiazepines)&#xD;
&#xD;
         11. Specific exclusions for the administration of varenicline not already specified: known&#xD;
             intolerance to varenicline or taking H2blockers (e.g., Cimetidine), quinolones, or&#xD;
             trimethoprim.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Coppola</last_name>
    <phone>203-737-2827</phone>
    <email>sabrina.coppola@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Lavery</last_name>
    <phone>203-737-2783</phone>
    <email>meaghan.lavery@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Coppola</last_name>
      <phone>203-737-2827</phone>
      <email>sabrina.coppola@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

